PRA Health Sciences (PRAH) Rating Lowered to Buy at BidaskClub

BidaskClub lowered shares of PRA Health Sciences (NASDAQ:PRAH) from a strong-buy rating to a buy rating in a research report report published on Friday.

A number of other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of PRA Health Sciences from a hold rating to a buy rating and set a $102.00 target price on the stock in a research note on Thursday. Mitsubishi UFJ Financial Group began coverage on shares of PRA Health Sciences in a research note on Friday, December 15th. They set an overweight rating and a $102.00 target price on the stock. Barclays began coverage on shares of PRA Health Sciences in a research note on Monday, December 11th. They set an overweight rating and a $94.00 target price on the stock. Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the company a buy rating in a research note on Friday, December 1st. Finally, Mizuho set a $87.00 target price on shares of PRA Health Sciences and gave the company a buy rating in a research note on Friday, December 1st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $91.92.

PRA Health Sciences (NASDAQ PRAH) traded up $0.40 on Friday, hitting $91.11. 345,786 shares of the company were exchanged, compared to its average volume of 471,880. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. PRA Health Sciences has a 52 week low of $54.08 and a 52 week high of $92.84. The stock has a market cap of $5,760.00, a PE ratio of 51.19, a price-to-earnings-growth ratio of 1.27 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter in the previous year, the company earned $0.64 EPS. PRA Health Sciences’s revenue for the quarter was up 23.7% on a year-over-year basis. equities research analysts anticipate that PRA Health Sciences will post 3.2 EPS for the current year.

In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 150,815 shares of company stock worth $13,642,620. 2.10% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. Magnetar Financial LLC bought a new stake in shares of PRA Health Sciences in the 3rd quarter worth about $5,010,000. State Board of Administration of Florida Retirement System increased its holdings in shares of PRA Health Sciences by 32.3% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 28,968 shares of the medical research company’s stock worth $2,173,000 after buying an additional 7,076 shares during the last quarter. Amalgamated Bank bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $370,000. Fred Alger Management Inc. increased its holdings in shares of PRA Health Sciences by 9.4% in the 2nd quarter. Fred Alger Management Inc. now owns 92,853 shares of the medical research company’s stock worth $6,965,000 after buying an additional 7,990 shares during the last quarter. Finally, Seven Eight Capital LP bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $840,000. Hedge funds and other institutional investors own 98.22% of the company’s stock.

WARNING: “PRA Health Sciences (PRAH) Rating Lowered to Buy at BidaskClub” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/08/pra-health-sciences-prah-rating-lowered-to-buy-at-bidaskclub.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

What are top analysts saying about PRA Health Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PRA Health Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit